Hi needle, IMO, Kazia's future cash requirements will continue...

Hi needle, IMO, Kazia's future cash requirements will continue to be sourced through the US ATM facility. It may be cost effective as a positive, but highly dilutive to existing shareholders from any negative or delayed company news releases.
A paxalisib Japan licence deal needs to be considered by management, so that the ATM facility can be paused,

"Under the ATM, Kazia may offer and sell via Oppenheimer up to US$ 35 million of its ordinary shares, in the form of American Depository Shares (ADSs), with each ADS representing ten ordinary shares. Kazia has entered into an Equity Distribution Agreement, dated as of 22 April 2022 (the Sales Agreement), with Oppenheimer, who will act as sales
agent.
Kazia Chairman, Iain Ross, commented, “ATM facilities are a common financing instrument for Nasdaq-listed biotech companies. We consider it prudent capital management for Kazia to have access to such a facility, so that it may respond most efficiently and most cost effectively to emerging investor demand.”Sales of ADSs under the ATM may be made from time to time, with the timing and amount of any sales to be determined by Kazia at its sole discretion, based on a variety of factors.
Kazia may determine to sell some, all, or none of the ADSs under the ATM and may terminate the facility at its discretion. Kazia, through Oppenheimer, may sell ADSs by any lawful method deemed to be an “at-the-market offering” defined by Rule 415(a)(4) under the Securities Act of 1933, as amended. Sales made through the ATM may be made at market prices prevailing at the time of a sale or at prices related to prevailing market prices. As a result, actual sales prices may vary."

Regards.